Launched on August 29th, Applied Integrin Sciences continues to promote their crowdfunding campaign to accelerate the development of their cancer fighting drug. The treatment is being designed to boost survival and quality of life for patients suffering ovarian, breast, prostate and other cancers. The initiative is being facilitated by the Alfred E. Mann Institute for Biomedical Engineering at USC, among others.
Applied Integrin Sciences, scientists’ at the University of Southern California Keck School of Medicine and the USC Norris Comprehensive Cancer Center discovered a novel cancer-fighting therapeutic drug which has demonstrated effective reduction of tumor growth and progression on six aggressive tumors: triple negative breast cancer, ovarian cancer, primary prostate cancer, prostate bone metastasis, melanoma, and brain cancer – glioblastoma. The company identified a new approach to treating ovarian cancer using its first cancer drug candidate that was funded by the National Cancer Institute of the National Institutes of Health, and is beginning the final research steps required by the FDA prior to submitting its application to conduct human clinical trials.
The company’s goal is to complete clinical drug development and achieve the same results as obtained in the laboratory. If achieved this novel cancer treatment could change the current standard of care and improve patient survival and quality of life. And if demonstrated safe in early clinical trials, the company also intends to embark on clinical development for other cancer indications including breast and prostate cancers.
Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!
